ALHC vs. SMMT: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and SMMT, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
SMMT towers over ALHC with a market cap of 18.74 billion USD, roughly 6.18 times the 3.03 billion USD of its peer.
SMMT dances to a riskier tune, sporting a beta of -0.95, while ALHC keeps it calmer at 1.33.
| Symbol | ALHC | SMMT |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | Summit Therapeutics Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Biotechnology |
| CEO | Mr. John E. Kao | Mr. Robert W. Duggan |
| Price | 15.33 USD | 25.41 USD |
| Market Cap | 3.03 billion USD | 18.74 billion USD |
| Beta | 1.327 | -0.948 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | March 5, 2015 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALHC and SMMT over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and SMMT based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- Both ALHC at -32.75 and SMMT at -77.90 have negative P/E values over the past twelve months. This reflects consistent losses rather than profits, meaning their current operations aren’t generating positive net income—a situation that could challenge their financial stability if prolonged.
- ALHC carries a negative Forward PEG of -1.11, hinting at analyst expectations of losses or shrinking earnings in the coming period—a potential warning for its future performance. On the flip side, SMMT at 8.05 sidesteps this concern with a more favorable outlook.
- SMMT has a negative Price-to-Free Cash Flow of -108.01, indicating it’s spent more cash than it’s brought in over the past year—a cash flow shortfall that raises questions about its operational sustainability. Meanwhile, ALHC at 159.00 maintains a positive cash position.
| Symbol | ALHC | SMMT |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | -77.90 |
| Forward PEG Ratio (TTM) | -1.11 | 8.05 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 0.00 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 54.47 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | -108.01 |
| EV-to-EBITDA (TTM) | -64.47 | -107.59 |
| EV-to-Sales (TTM) | 0.86 | 0.00 |
| EV-to-Free Cash Flow (TTM) | 136.01 | -106.83 |
Dividend Comparison
Neither ALHC nor SMMT pays dividends, suggesting both reinvest all profits into growth—likely expansion or innovation—favoring long-term value over immediate income.
| Symbol | ALHC | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and SMMT, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALHC at -2.98 and SMMT at -30.27 both scrape by with interest coverage under 1.5. Earnings are stretched thin against interest bills, leaving little wiggle room if profits drop.
| Symbol | ALHC | SMMT |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 10.63 |
| Quick Ratio (TTM) | 1.69 | 10.63 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 0.02 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.02 |
| Interest Coverage Ratio (TTM) | -2.98 | -30.27 |